CCIA
SPRY icon

Campbell & Co Investment Adviser’s ARS Pharmaceuticals SPRY Stock Holding History

Campbell & Co Investment Adviser’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60,525
Closed -$608K – 1385
2025
Q3 		$608K Buy
+60,525
New +$869K 0.05% 635
2024
Q4 		– Sell
-21,446
Closed -$311K – 1346
2024
Q3 		$311K Buy
+21,446
New +$255K 0.02% 887

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Campbell & Co Investment Adviser's SPRY Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of ARS Pharmaceuticals (SPRY) in Q4 2025, closing a stake of 60,525 shares — an estimated $608K sold.

Campbell & Co Investment Adviser first reported a position in SPRY in Q3 2024 and held it in 2 quarters. The position peaked at $608K in Q3 2025. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Campbell & Co Investment Adviser reported no remaining ARS Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 60,525 ARS Pharmaceuticals shares in Q4 2025, an estimated $608K.
  • Campbell & Co Investment Adviser first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Campbell & Co Investment Adviser's ARS Pharmaceuticals position peaked at $608K in Q3 2025.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.